Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note published on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners assumed coverage on Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective for the company.

Lipocine Trading Up 1.0 %

NASDAQ LPCN opened at $5.20 on Friday. The company has a market cap of $27.82 million, a P/E ratio of -6.84 and a beta of 1.24. The company has a fifty day simple moving average of $5.13 and a 200 day simple moving average of $5.55. Lipocine has a 12-month low of $2.40 and a 12-month high of $11.79.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Sell-side analysts predict that Lipocine will post -0.78 EPS for the current year.

Hedge Funds Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Renaissance Technologies LLC increased its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,697 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned approximately 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.